Triveni Bio Raises $115M Series B Financing to Advance Antibody Treatments for I&I DisordersTriveni Bio Inc. raised $115 million to accelerate its antibody therapies for immune and inflammatory disorders, focusing on novel pathways and advanced treatment efficacy.
Exercise bouts could improve efficacy of cancer drugModerate-to-vigorous exercise boosts effectiveness of antibody therapies for chronic lymphocytic leukaemia.